Latest

3 stories

Hide weekly roundups

Friday, November 6

Clinical readoutBioNTech SE Evaxion Biotech A/S Genmab A/SUpdated

Evaxion presents new EVX-01 immune data at SITC, showing ex vivo T-cell detection

Data presented at SITC 2026 found neoantigen-specific T cells detectable directly ex vivo and a strong statistical link between AI-Immunology predictions and actual T-cell responses.

SEC filing, Drugs@FDA (9)

Wednesday, October 21

Clinical readoutEikon Therapeutics Genmab A/S Immatics N.V.

Imunon agrees to sell ThermoDox rights to VoxelDox Therapeutics

The October 20, 2026 deal gives Imunon equity, milestone payments up to $16.5 million, and royalties, while it keeps focus on its Phase 3 OVATION 3 trial.

SEC filing (5)

Thursday, October 1

PeopleNanobiotix S.A.

Nanobiotix names Arnd Christ as new chief financial officer

Christ, former Immatics CFO, takes over October 1, 2026, replacing Bart Van Rhijn after his five-year tenure at the company.

SEC filing